Changing the standard of care for elderly multiple myeloma patients
The epigenetics of multiple myeloma and the rationale for HDAC inhibitors
What to look for in novel CLL therapies
Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
Is the CR of MM patients a good objective for treatment?